EARLY VEDOLIZUMAB TROUGH LEVELS ARE NOT ASSOCIATED WITH A SHORT-TERM RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Pudilova, Karolina
Duricova, Dana
Kolar, Martin
Malickova, Karin
Hruba, Veronika
Machkova, Nadezda
Vanickova, Radka
Mitrova, Katarina
Lukas, Martin
Vasatko, Martin
Lukas, Milan
Bortlik, Martin
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1894
引用
收藏
页码：S877 / S877
页数：1
相关论文
共 50 条
  • [31] Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
    Levartovsky, Asaf
    Cohen, Ido
    Abitbol, Chaya Mushka
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Kopylov, Uri
    Ben-Horin, Shomron
    Ungar, Bella
    BIOMEDICINES, 2023, 11 (06)
  • [32] VEDOLIZUMAB DRUG LEVELS ARE NOT ASSOCIATED WITH OUTCOMES OR DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE
    Shields, Stephanie
    Seenan, John Paul
    Nowell, Emma
    Dunlop, Allan
    Galloway, Peter
    Macdonald, Jonathan
    GUT, 2021, 70 : A122 - A123
  • [33] Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease
    Yarur, A.
    Bruss, A.
    Fox, C.
    Beniwal-Patel, P.
    Patel, A.
    Berens, B.
    Naik, S.
    Stein, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S64 - S65
  • [34] VEDOLIZUMAB LEVELS DURING INDUCTION ARE ASSOCIATED WITH LONG-TERM CLINICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Yarur, Andres J.
    Bruss, Alexandra
    Berens, Brandon
    Fox, Caroline
    Beniwal-Patel, Poonam M.
    Patel, Amir
    Ungaro, Ryan C.
    Dubinsky, Marla
    Naik, Snehal
    Stein, Daniel J.
    GASTROENTEROLOGY, 2018, 154 (06) : S827 - S828
  • [35] Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels
    Huettemann, Eva
    Muzalyova, Anna
    Groehl, Katharina
    Nagl, Sandra
    Fleischmann, Carola
    Ebigbo, Alanna
    Classen, Johanna
    Wanzl, Julia
    Prinz, Friederike
    Mayr, Patrick
    Schnoy, Elisabeth
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [36] Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, J.
    Sever, N.
    Ferkolj, I.
    Stabuc, B.
    Smrekar, N.
    Kozelj, M.
    Novak, G.
    Gils, A.
    Drobne, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S414
  • [37] VEDOLIZUMAB TROUGH LEVELS AT WEEK 6 PREDICT ENDOSCOPIC AND CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kozelj, Matic
    Novak, Gregor
    Gils, Ann
    Drobne, David
    GASTROENTEROLOGY, 2018, 154 (06) : S819 - S819
  • [38] Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease
    Buffone, Elisa
    Gupta, Shaan
    Al Ibrahim, Bashaar
    Marshall, John K.
    Halder, Smita
    Tse, Frances
    Albashir, Siwar
    Morgan, David
    Lumb, Barry
    Armstrong, David
    Narula, Neeraj
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2022, 56 (09) : 794 - 797
  • [39] POOR OUTCOMES ASSOCIATED WITH SHORT-TERM AND LONG-TERM OPIOID USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Telfer, Laura
    Dalessio, Shannon
    Tinsley, Andrew
    Coates, Matthew
    GASTROENTEROLOGY, 2023, 164 (06) : S454 - S454
  • [40] Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
    Elisa K. Boden
    Donna M. Shows
    Michael V. Chiorean
    James D. Lord
    Digestive Diseases and Sciences, 2018, 63 : 2419 - 2429
12345